<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<article xml:lang="EN" article-type="letter">

<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id>
<journal-id journal-id-type="publisher-id">JKMS</journal-id>
<journal-title>Journal of Korean Medical Science</journal-title>
<issn pub-type="ppub">1011-8934</issn>
<issn pub-type="epub">1598-6357</issn>
<publisher>
<publisher-name>The Korean Academy of Medical Sciences</publisher-name>
</publisher>
</journal-meta>

<article-meta>

<article-id pub-id-type="doi">10.3346/jkms.2011.26.6.850</article-id>

<article-categories>
<subj-group>
<subject>Correspondence</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Author Response: Acute Effects of Intravenous Administration of Pamidronate in Patients with Osteoporosis</article-title>
</title-group>

<contrib-group>

<contrib contrib-type="author" corresp="yes">
<name>
<surname>Park</surname>
<given-names>Won</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>

</contrib-group>

<aff id="A1">Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, Korea.</aff>

<author-notes>
<corresp>
Address for Correspondence: Won Park, MD. Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, 27 Inhang-ro, Jung-gu, Incheon 400-711, Korea. Tel: +82.32-8903483, Fax: +82.32-8826578, <email>parkwon@inha.ac.kr</email>
</corresp>
</author-notes>

<pub-date pub-type="ppub">
<month>06</month>
<year>2011</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>05</month>
<year>2011</year>
</pub-date>
<volume>26</volume>
<issue>6</issue>
<fpage>850</fpage>
<lpage>850</lpage>
<permissions>
<copyright-statement>&#x00A9; 2011 The Korean Academy of Medical Sciences.</copyright-statement>
<copyright-year>2011</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
<p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
</permissions>

</article-meta>
</front>

<body>

  <p>Dear Editor</p>

  <p>We appreciate the comments by Marcuzzi. Marcuzzi et al. (<xref ref-type="bibr" rid="B1">1</xref>) and we (<xref ref-type="bibr" rid="B2">2</xref>) showed that the pamidronate stimulates the secretion of proinflammatory cytokines in mouse model and in human respectively. Although we measured the acute phase response caused by intermittent large dose aminobisphosphate whereas Marcuzzi emphasized on the inflammatory effect of aminobisphosphate and its reversal by geraniol, the isoprenoid. Acute phase response, a notorious side effect of aminobisphosphate, typically occurs in about one third of patients taking aminobisphophate for the first time (<xref ref-type="bibr" rid="B3">3</xref>). It was previously reported that after administration of large dose such as the dose for malignancy, proinflammatory cytokines were stimulated and thus, play a key role in acute phase response (<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>). We demonstrated the elevation of proinflammatory cytokines at the usual dose for osteoporosis. Marcuzzi et al. (<xref ref-type="bibr" rid="B1">1</xref>) successfully revealed that the inflammatory reaction caused by pamidronate could be alleviated by geraniol and we hope that the exogenous geraniol could help to lessen the acute phase response. In conclusion, we both agree with induction of inflammatory response by pamidronate. Further investigation is required on finding the way to reduce the acute phase response that does not abrogate the therapeutic benefit of the aminobisphosphonate, including the exogenous geraniol.</p>

</body>

<back>

<ref-list>
  <ref id="B1">
    <label>1</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Marcuzzi</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Crovella</surname>
          <given-names>S</given-names>
        </name>
        <name>
          <surname>Pontillo</surname>
          <given-names>A</given-names>
        </name>
      </person-group>
      <article-title>Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency</article-title>
      <source>In Vivo</source>
      <year>2011</year>
      <volume>25</volume>
      <fpage>87</fpage>
      <lpage>92</lpage>
    </nlm-citation>
  </ref>

  <ref id="B2">
    <label>2</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Lim</surname>
          <given-names>MJ</given-names>
        </name>
        <name>
          <surname>Kwon</surname>
          <given-names>SR</given-names>
        </name>
        <name>
          <surname>Park</surname>
          <given-names>SG</given-names>
        </name>
        <name>
          <surname>Park</surname>
          <given-names>W</given-names>
        </name>
      </person-group>
      <article-title>Acute effects of intravenous administration of pamidronate in patients with osteoporosis</article-title>
      <source>J Korean Med Sci</source>
      <year>2010</year>
      <volume>25</volume>
      <fpage>1277</fpage>
      <lpage>1283</lpage>
    </nlm-citation>
  </ref>

  <ref id="B3">
    <label>3</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Adami</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Bhalla</surname>
          <given-names>AK</given-names>
        </name>
        <name>
          <surname>Dorizzi</surname>
          <given-names>R</given-names>
        </name>
        <name>
          <surname>Montesanti</surname>
          <given-names>F</given-names>
        </name>
        <name>
          <surname>Rosini</surname>
          <given-names>S</given-names>
        </name>
        <name>
          <surname>Salvagno</surname>
          <given-names>G</given-names>
        </name>
        <name>
          <surname>Lo Cascio</surname>
          <given-names>V</given-names>
        </name>
      </person-group>
      <article-title>The acute-phase response after bisphosphonate administration</article-title>
      <source>Calcif Tissue Int</source>
      <year>1987</year>
      <volume>41</volume>
      <fpage>326</fpage>
      <lpage>331</lpage>
    </nlm-citation>
  </ref>

  <ref id="B4">
    <label>4</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Schweitzer</surname>
          <given-names>DH</given-names>
        </name>
        <name>
          <surname>Oostendorp-Van de Ruit</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Van der Pluijm</surname>
          <given-names>G</given-names>
        </name>
        <name>
          <surname>L&#x00F6;wik</surname>
          <given-names>CW</given-names>
        </name>
        <name>
          <surname>Papapoulos</surname>
          <given-names>SE</given-names>
        </name>
      </person-group>
      <article-title>Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate</article-title>
      <source>J Bone Miner Res</source>
      <year>1995</year>
      <volume>10</volume>
      <fpage>956</fpage>
      <lpage>962</lpage>
    </nlm-citation>
  </ref>

  <ref id="B5">
    <label>5</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Sauty</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Pecherstorfer</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Zimmer-Roth</surname>
          <given-names>I</given-names>
        </name>
        <name>
          <surname>Fioroni</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Juillerat</surname>
          <given-names>L</given-names>
        </name>
        <name>
          <surname>Markert</surname>
          <given-names>M</given-names>
        </name>
        <name>
          <surname>Ludwig</surname>
          <given-names>H</given-names>
        </name>
        <name>
          <surname>Leuenberger</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Burckhardt</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Thiebaud</surname>
          <given-names>D</given-names>
        </name>
      </person-group>
      <article-title>Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy</article-title>
      <source>Bone</source>
      <year>1996</year>
      <volume>18</volume>
      <fpage>133</fpage>
      <lpage>139</lpage>
    </nlm-citation>
  </ref>

  <ref id="B6">
    <label>6</label>
    <nlm-citation citation-type="journal">
      <person-group person-group-type="author">
        <name>
          <surname>Thi&#x00E9;baud</surname>
          <given-names>D</given-names>
        </name>
        <name>
          <surname>Sauty</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Burckhardt</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Leuenberger</surname>
          <given-names>P</given-names>
        </name>
        <name>
          <surname>Sitzler</surname>
          <given-names>L</given-names>
        </name>
        <name>
          <surname>Green</surname>
          <given-names>JR</given-names>
        </name>
        <name>
          <surname>Kandra</surname>
          <given-names>A</given-names>
        </name>
        <name>
          <surname>Zieschang</surname>
          <given-names>J</given-names>
        </name>
        <name>
          <surname>Ibarra de Palacios</surname>
          <given-names>P</given-names>
        </name>
      </person-group>
      <article-title>An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates</article-title>
      <source>Calcif Tissue Int</source>
      <year>1997</year>
      <volume>61</volume>
      <fpage>386</fpage>
      <lpage>392</lpage>
    </nlm-citation>
  </ref>

</ref-list>

</back>

</article>